Home

EIRY ROBERTS

CIK 1727606 · Chief Medical Officer · last filed 2026-05-26

EIRY ROBERTS is a Chief Medical Officer who has filed 54 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for BHC, was dated May 26, 2026. Across all open-market trades the lifetime net is −$21.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.2M across reported positions. 48 SEC filings were submitted jointly with NEUROCRINE BIOSCIENCES INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.19M

Companies

3

Total Filings

54

Lifetime Open-Market Net

-$21.23M

Filer Profile

Reported Address
C/O NEUROCRINE BIOSCIENCES, INC.
12780 EL CAMINO REAL
SAN DIEO, CA 92130
Related Filers
NEUROCRINE BIOSCIENCES INC — 48 joint filings, latest 2025-02-14
Bausch Health Companies Inc. — 2 joint filings, latest 2026-05-26
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BHC Director 45,871 $5.64 $258.7K $0 1 2026-05-26
AMICUS THERAPEUTICS, INC. (FOLD) Delisted Director 0 $14.49 $0 $0 6 2026-04-27
NBIX Chief Medical Officer 34,252 $143.96 $4.93M -$21.23M 35 2025-02-14

Recent Filings

54 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-26 BHC Grant (A) +45,871 $0 EDGAR
2026-04-27 AMICUS THERAPEUTICS, INC. (FOLD) Delisted Disp (D) −76,275 -$1.11M EDGAR
2025-06-06 AMICUS THERAPEUTICS, INC. (FOLD) Delisted Grant (A) +20,414 $0 EDGAR
2025-02-14 NBIX Notice (144) −500 -$57.5K EDGAR
2025-02-14 NBIX Mixed +2,387 -$258.3K EDGAR
2025-02-13 NBIX Notice (144) −604 -$70.8K EDGAR
2025-02-13 NBIX Notice (144) −1,114 -$130.5K EDGAR
2025-02-12 NBIX Mixed +880 -$115.9K EDGAR
2025-02-10 NBIX Notice (144) −980 -$120.2K EDGAR
2025-02-04 NBIX Mixed +1,312 -$222.6K EDGAR
Showing 1–10 of 54
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.